Table 2. Association of PD-L1 of primary and metastasis with clinical factor.
| Primary PD-L1 IHC | P-value | Metastatic PD-L1 IHC | P-value | Primary PD-L1 ISH | P-value | Metastatic PD-L1 ISH | P-value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| positive | negative | positive | negative | positive | negative | positive | negative | |||||
| Histology | 0.005 | 0.012 | 0.691 | 0.463 | ||||||||
| Adenocarcinoma | 2 (5.4%) | 26 (70.3%) | 3 (8.1%) | 25 (67.6%) | 9 (24.3%) | 19 (51.4%) | 7 (18.9%) | 21 (56.8%) | ||||
| Squamous carcinoma | 5 (13.5%) | 4 (10.8%) | 5 (13.5%) | 4 (10.8%) | 4 (10.8%) | 5 (13.5%) | 3 (8.1%) | 6 (16.2%) | ||||
| EGFR mutation | 0.056 | 0.038 | 0.711 | 0.832 | ||||||||
| Mutant | 0 (0%) | 11 (29.7%) | 0 (0%) | 11 (29.7%) | 3 (8.1%) | 8 (21.6%) | 3 (8.1%) | 8 (21.6%) | ||||
| Wild type | 7 (18.9%) | 19 (51.4%) | 8 (21.6%) | 18 (48.6%) | 10 (27.0%) | 16 (43.2%) | 7 (18.9%) | 19 (51.4%) | ||||
| Smoking history | 0.064 | 0.672 | 0.602 | 0.639 | ||||||||
| Current/ex smoker | 7 (18.9%) | 19 (51.4%) | 5 (13.5%) | 21 (56.8%) | 9 (24.3%) | 17 (45.9%) | 7 (18.9%) | 19 (51.4%) | ||||
| Never smoker | 0 (0%) | 11 (29.7%) | 3 (8.1%) | 8 (21.6%) | 4 (10.8%) | 7 (18.9%) | 3 (8.1%) | 8 (21.6%) | ||||